Topic title: cancer treatment technologies for low-resource settings project title: PRV311: a standalone, safe, effective, and affordable treatment for early-stage cervical cancer in lmics
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91022C00020
- Awardee
-
Privo Technologies, Inc. UEI E6ACGUBJMQC5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,049,944
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Pre-Solicitation · PHS20221 · Posted Jul 12, 2021
- Contract value 100% obligated
- $2,049,944.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 13 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Peabody, MA 01960, USA
- Research
- SBIR Program Phase II Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $2,049,944 |
About this award
Privo Technologies, Inc. has been awarded a $2,049,944 firm fixed price definitive contract by the National Institutes of Health National Cancer Institute (NIH NCI) to conduct research and development under Phase II of the Small Business Innovation Research (SBIR) program. This contract is being performed under a total small business set aside solicitation issued by NIH and the Centers for Disease Control and Prevention seeking proposals aligned with developing medical technologies, diagnostics, vaccines, cell therapies and other innovative solutions to advance public health goals. Specifically, Privo Technologies will work on PRV311, a standalone, safe, effective and affordable treatment for early-stage cervical cancer in low- and middle-income countries under the project title "PRV311: A Standalone, Safe, Effective, and Affordable Treatment for Early-Stage Cervical Cancer in LMICs." All work will be conducted by Privo Technologies at their Peabody, Massachusetts facility over a 24 month period ending September 2024.
Quick answers
Who was awarded contract 75N91022C00020?
75N91022C00020 was awarded to Privo Technologies, Inc. by National Cancer Institute (National Institutes of Health) on September 15, 2022.
How much is contract 75N91022C00020 worth?
The government has obligated $2,049,944 on 75N91022C00020.
Was contract 75N91022C00020 competed?
The extent of competition for 75N91022C00020 was full and open competition after exclusion of sources. The government received 13 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award